Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

abstract：:Very long delay to engraftment (or non-engraftment) was observed in eight patients presenting common immunological features, i.e. excess of blood and bone marrow lymphocytes coexpressing CD8 and CD57 (HNK1) antigens. They were therefore treated by CD8 immunotherapy. Such treatment induced a complete clearance of CD8+,...

journal_title：Bone marrow transplantation

authors： Favrot M,Philip T,Combaret V,Lemerle J,Marie JP,Bernard A

更新日期：1990-01-01 00:00:00

abstract：:In order to optimize peripheral blood stem cell (PBSC) collection for transplantation, absolute CD34 counts are necessary to determine the exact time-point for sufficient leukapheresis. In an effort to establish and to validate a rapid and reproducible assay for PBSC enumeration, different recommendations for selectio...

journal_title：Bone marrow transplantation

authors： Leuner S,Arland M,Kahl C,Jentsch-Ullrich K,Franke A,Höffkes HG

更新日期：1998-10-01 00:00:00

abstract：:Generalized multiple cutaneous tumors developed in a 60-year-old Japanese man. Skin biopsy revealed atypical large T lymphocytes infiltrating the dermis. CD30 staining was negative in the tumor cells. The diagnosis of CD30-negative cutaneous large T cell lymphoma was made. Axial and inguinal lymphadenopathy was presen...

journal_title：Bone marrow transplantation

authors： Nishio M,Koizumi K,Endo T,Takashima H,Haseyama Y,Fujimoto K,Yamamoto S,Kobayashi H,Koike T,Sawada K

更新日期：2000-06-01 00:00:00

abstract：:We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

journal_title：Bone marrow transplantation

authors： Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

更新日期：2006-11-01 00:00:00

abstract：:Despite its potential to cause myocardial damage, high-dose CY in doses up to 200 mg/kg is an integral part of preparative regimens for BMT. Conventional tests, such as an electrocardiogram or echocardiogram, have lacked sensitivity in prediction of cardiotoxicity in this patient population. We prospectively compared ...

journal_title：Bone marrow transplantation

authors： Gardner SF,Lazarus HM,Bednarczyk EM,Creger RJ,Miraldi FD,Leisure G,Green JA

更新日期：1993-08-01 00:00:00

abstract：:We performed a randomized study to compare 'G-CSF alone' (administered at dose of 10 mcg/kg/day) and 'cyclophosphamide plus G-CSF' (cyclophosphamide at dose of 4 g/m(2) and G-CSF at dose of 10 microg/kg/day), as PBPC mobilization schedules in 52 patients with NHL or HD. Randomization was stratified according to the am...

journal_title：Bone marrow transplantation

authors： Milone G,Leotta S,Indelicato F,Mercurio S,Moschetti G,Di Raimondo F,Tornello A,Consoli U,Guido G,Giustolisi R

更新日期：2003-05-01 00:00:00

abstract：:The preimmune status of the early gestational age fetus provides a permissive environment that bypasses the immunological barrier and permits the engraftment and expression of hemopoietic stem cells (HSC). We used in utero approach to establish long term (greater than 2 years) engraftment and expression of human fetal...

journal_title：Bone marrow transplantation

authors： Zanjani ED,Pallavacini MG,Ascensao JL,Flake AW,Harrison MR,Tavassoli M

更新日期：1992-01-01 00:00:00

abstract：:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

journal_title：Bone marrow transplantation

authors： Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

更新日期：2006-05-01 00:00:00

abstract：:The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The comple...

journal_title：Bone marrow transplantation

authors： Paczesny S,Hanauer D,Sun Y,Reddy P

更新日期：2010-01-01 00:00:00

abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

journal_title：Bone marrow transplantation

authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

更新日期：2015-06-01 00:00:00

abstract：:Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...

journal_title：Bone marrow transplantation

authors： Bornhäuser M,Thiede C,Schuler U,Platzbecker U,Freiberg-Richter J,Helwig A,Plettig R,Röllig C,Naumann R,Kroschinsky F,Neubauer A,Ehninger G

更新日期：2000-07-01 00:00:00

abstract：:A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

journal_title：Bone marrow transplantation

authors： Khan AM,Yamase H,Tutschka PJ,Bilgrami S

更新日期：1997-05-01 00:00:00

abstract：:We have evaluated bone marrow morphology, percentage of bone marrow CD34(+) cells, proliferative activity of bone marrow precursors, clonogenic assay (BFU-E and CFU-GM) in short-term bone marrow cultures, and bone marrow cell apoptosis, together with serum TNF-alpha and IL-6, in 16 chronic, refractory RA patients, as ...

journal_title：Bone marrow transplantation

authors： Porta C,Caporali R,Epis O,Ramaioli I,Invernizzi R,Rovati B,Comolli G,Danova M,Montecucco C

更新日期：2004-04-01 00:00:00

abstract：:Few studies have addressed the incidence of graft-versus-host disease (GVHD) or survival after ABO-incompatible allogeneic peripheral blood stem cell transplantation (PBSCT). We analyzed the clinical outcome of ABO incompatibility after allogeneic PBSCT. A total of 89 consecutive adult patients with hematological dise...

journal_title：Bone marrow transplantation

authors： Kim JG,Sohn SK,Kim DH,Baek JH,Lee KB,Min WS,Kim CC,Lee MH,Lee JJ,Chung IJ,Kim HJ,Lee JW

更新日期：2005-03-01 00:00:00

abstract：:In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

journal_title：Bone marrow transplantation

authors： Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

更新日期：1998-07-01 00:00:00

abstract：:A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

journal_title：Bone marrow transplantation

authors： Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

更新日期：1996-07-01 00:00:00

abstract：:Eighteen patients with chronic myelogenous leukemia (CML) in chronic (9 patients) or advanced phases (9 patients) underwent autologous bone marrow transplantation (BMT) with a preparative regimen using high doses of cyclophosphamide, etoposide and total body irradiation (CY-VP16-TBI): cyclophosphamide 60 mg/kg daily o...

journal_title：Bone marrow transplantation

authors： Kantarjian HM,Talpaz M,Andersson B,Khouri I,Giralt S,Rios MB,Champlin R,Hester J,Deisseroth AB

更新日期：1994-07-01 00:00:00

abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...

journal_title：Bone marrow transplantation

authors： Bashey A,Solomon SR

更新日期：2014-08-01 00:00:00

abstract：:Children who undergo bone marrow transplantation (BMT) are at risk for Pneumocystis carinii pneumonia (PCP). Prophylaxis using trimethoprim/sulfamethoxazole (TMP/SMX) is highly effective but the incidence of adverse drug reactions is significant. We retrospectively reviewed 33 pediatric BMT (25 allogeneic and eight au...

journal_title：Bone marrow transplantation

authors： Maltezou HC,Petropoulos D,Choroszy M,Gardner M,Mantzouranis EC,Rolston KV,Chan KW

更新日期：1997-11-01 00:00:00

abstract：:Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its effect in acute steroid-resistant/dependent GVHD. In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD). Twelve patients were included in this study; of...

journal_title：Bone marrow transplantation

authors： Shapira MY,Abdul-Hai A,Resnick IB,Bitan M,Tsirigotis P,Aker M,Gesundheit B,Slavin S,Or R

更新日期：2009-02-01 00:00:00

abstract：:We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

journal_title：Bone marrow transplantation

authors： Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1992-07-01 00:00:00

abstract：:Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

journal_title：Bone marrow transplantation

authors： Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

更新日期：2004-09-01 00:00:00

abstract：:The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormo...

journal_title：Bone marrow transplantation

authors： Isfan F,Kanold J,Merlin E,Contet A,Sirvent N,Rochette E,Poiree M,Terral D,Carla-Malpuech H,Reynaud R,Pereira B,Chastagner P,Simeoni MC,Auquier P,Michel G,Deméocq F

更新日期：2012-05-01 00:00:00

abstract：:We report here the first case of large granular lymphocytes (LGL) expansion following non-myeloablative allo-BMT for chronic myeloid leukemia. We characterized the morphologic, phenotypic and functional features of the LGL subset amplified in vivo 14 months after allo-BMT. Our results indicate that LGL can mediate in ...

journal_title：Bone marrow transplantation

authors： Mohty M,Faucher C,Gaugler B,Vey N,Sainty D,Arnoulet C,Mozziconacci MJ,Isnardon D,Gastaut JA,Maraninchi D,Olive D,Blaise D

更新日期：2001-12-01 00:00:00

abstract：:Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

journal_title：Bone marrow transplantation

authors： D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

更新日期：2001-09-01 00:00:00

abstract：:For patients with ALL who relapse following allo-SCT, only a second SCT provides a realistic chance for long-term disease remission. We retrospectively analyzed the outcomes of 31 patients with relapsed ALL after a prior allo-SCT, who received a second SCT (SCT2) at our center. With a median follow-up of 3 years, 1- a...

journal_title：Bone marrow transplantation

authors： Poon LM,Bassett R Jr,Rondon G,Hamdi A,Qazilbash M,Hosing C,Jones RB,Shpall EJ,Popat UR,Nieto Y,Worth LL,Cooper L,De Lima M,Champlin RE,Kebriaei P

更新日期：2013-05-01 00:00:00

abstract：:Allogeneic haematopoietic SCT is a standard therapy for many patients with haematological diseases. A major aim of public umbilical cord blood (UCB) banking is to establish an inventory with a large HLA diversity. Few studies have compared HLA diversity between UCB banks and volunteer unrelated donor (VUD) registries ...

journal_title：Bone marrow transplantation

authors： Meyer-Monard S,Passweg J,Troeger C,Eberhard HP,Roosnek E,de Faveri GN,Chalandon Y,Rovo A,Kindler V,Irion O,Holzgreve W,Gratwohl A,Müller C,Tichelli A,Tiercy JM

更新日期：2009-05-01 00:00:00

abstract：:To analyze the incidence, characteristics and risk factors of hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (allo-RIC), we conducted a retrospective study in three Spanish centers. We analyzed 452 consecutive patients receiving allo-RIC. Of these, 92 patient...

journal_title：Bone marrow transplantation

authors： Barba P,Martino R,Perez-Simón JA,Fernández-Avilés F,Piñana JL,Valcárcel D,Campos-Varela I,Lopez-Anglada L,Rovira M,Novelli S,Lopez-Corral L,Carreras E,Sierra J

更新日期：2012-10-01 00:00:00

abstract：:Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple mye...

journal_title：Bone marrow transplantation

authors： Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:Using in situ hybridization with an X and Y chromosome probe mixture, 106 bone marrow samples from 38 patients with malignant and non-malignant hematological diseases who received sex-mismatched allogeneic hematopoietic progenitor cell transplants (PCT) in a single institution within short-term intervals (1, 3, 6, 12,...

journal_title：Bone marrow transplantation

authors： Ortega M,Escudero T,Caballín MR,Olivé T,Ortega JJ,Coll MD

更新日期：1999-07-01 00:00:00